AJP - Lung Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol (October 25, 2002). doi:10.1152/ajplung.00183.2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/2/L333    most recent
00183.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sood, H. S.
Right arrow Articles by Tyagi, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sood, H. S.
Right arrow Articles by Tyagi, S. C.

Articles in PresS, published online ahead of print October 25, 2002
Am J Physiol Lung Cell Mol Physiol, 10.1152/ajplung.00183.2002
Submitted on June 7, 2002
Accepted on October 4, 2002

Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia

Harpreet S. Sood1, Matthew J. Hunt1, and Suresh C. Tyagi1*

1 Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

* To whom correspondence should be addressed. E-mail: styagi{at}physiology.umsmed.edu.

To test the hypothesis that endothelial dysfunction in hyperhomocysteinemia (HHcy) was due to increased levels of nitrotyrosine and matrix metalloproteinase (MMP) activity in response of antagonism of peroxisome proliferator activated receptor{alpha} (PPAR{alpha}), cystathionine ß synthase(CBS) -/+ mice were bred, tail tissue was analyzed for genotype by PCR, and tail vein blood was analyzed for homocysteine (Hcy) by spectrofluorometry in 50 male offsprings of 20±3 g at the age of 8 weeks. Mice were separated based on plasma Hcy 4.5±1.5 (+/+, wildtype), and 11.7±3.4 µmoles/liter (-/+), p<0.001 compared with +/+. To induce PPAR{alpha}, 10 -/+ and 10 +/+ mice were administered with 0.08 mg/ml ciprofibrate (CF) in drinking water for 12 weeks, and grouped: 1) wildtype; 2) wildtype + CF; 3) CBS; 4) CBS + CF (n=6 in each group). In these 4 respective study groups of mice: plasma Hcy was 3.0±0.2, 2.5±1.2, 15.2±2.6 (p<0.05 compared with wildtype), 11.0±2.9 µmoles/liter. Mouse urinary protein was 110±11, 86±6, 179±13, 127±9 µg/day/kg by Bio-Rad dye binding assay. Aortic nitrotyrosine was 0.099±0.012, 0.024±0.004, 0.132±0.024 (p<0.01 compared with wildtype), 0.05±0.01 (scan unit) by Western analysis. MMP-2 activity was 0.053±0.010, 0.024±0.002, 0.039±0.009, 0.017±0.006 (scan unit) by zymography. MMP-9 was specifically induced in CBS -/+ mice, and inhibited by CF treatment. Systolic blood pressure (SP) was 90±2, 88±16, 104±8 (p<0.05 compared with wildtype), 96±3 mmHg. The heart rate was 426±75, 387±63, 466±40, 458±38 beats/min. The aortic wall stress,(SP.radius2/wall thickness)/2.(radius+wall thickness), was 10.2±1.9, 9.7±0.2, 16.6±0.8 (p<0.05 compared with wildtype), 13.1±2.1 dynes/cm2. The results suggested that Hcy increased aortic wall stress by increasing nitrotyrosine and MMP-9 activity. The fibrate reduced MMP-9 in CBS -/+, and MMP-2 activity in both CBS -/+ and wildtype mice. The treatment with fibrate ameliorated endothelial dysfunction in CBS -/+ mice.




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. V. Ovechkin, N. Tyagi, U. Sen, D. Lominadze, M. M. Steed, K. S. Moshal, and S. C. Tyagi
3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice
Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L905 - L911.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
W. E. Rodriguez, N. Tyagi, I. G. Joshua, J. C. Passmore, J. T. Fleming, J. C. Falcone, and S. C. Tyagi
Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus
Am J Physiol Renal Physiol, September 1, 2006; 291(3): F694 - F701.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. M. Devlin and S. R. Lentz
ApoA-I: A Missing Link Between Homocysteine and Lipid Metabolism?
Circ. Res., March 3, 2006; 98(4): 431 - 433.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis
Matrix Metalloproteinases and Diabetic Vascular Complications
Angiology, March 1, 2005; 56(2): 173 - 189.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. C. Tyagi, W. Rodriguez, A. M. Patel, A. M. Roberts, J. C. Falcone, J. C. Passmore, J. T. Fleming, and I. G. Joshua
Hyperhomocysteinemic Diabetic Cardiomyopathy: Oxidative Stress, Remodeling, and Endothelial-Myocyte Uncoupling
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 1 - 10.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. M. Faraci
Hyperhomocysteinemia: A Million Ways to Lose Control
Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 371 - 373.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2002 by the American Physiological Society.